Browse by author
Lookup NU author(s): Dr Kenneth RankinORCiD, Dr Zakareya Gamie
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
© 2025 Jeys et al. Aims: The Birmingham Orthopaedic Oncology Meeting (BOOM), held in January 2024, convened 309 delegates from 53 countries to discuss and refine 21 consensus statements on the optimal management of chondrosarcoma. Methods: With representation from Europe (43%; n = 133), North America (17%; n = 53), South America (16%; n = 49), Asia (13%; n = 40), Australasia (5%; n = 16), the Middle East (4%; n = 12), and Africa (2%; n = 6), the combined experience of treating bone sarcomas among attendees totalled approximately 30,000 cases annually, equivalent to 66 years of experience in the UK alone. The meeting's process began with the formation of a local organizing committee, regional leads, and a scientific committee comprising representatives from 150 specialist units across 47 countries. Supported by major orthopaedic oncology organizations, the meeting used a modified Delphi process to develop consensus statements through online questionnaires, thematic groupings, narrative reviews, and anonymous pre-meeting polling. Results: Strong (> 80%) consensus was achieved on 19 out of 21 statements, reflecting agreement among delegates. Key areas of consensus included the role of radiology in diagnosis and surveillance, the management of locally recurrent disease, and the treatment of dedifferentiated chondrosarcoma. Notably, there was agreement that routine chemotherapy has no role in chondrosarcoma treatment, and radiological surveillance is safe for intraosseous chondrosarcomas. Despite the overall consensus, areas of controversy remain, particularly regarding the treatment of atypical cartilage tumours and surgical margins. These unresolved issues underscore the need for further research and collaboration within the orthopaedic oncology community. Conclusion: BOOM represents the largest global consensus meeting in orthopaedic oncology, providing valuable guidance for clinicians managing chondrosarcoma worldwide. The consensus statements offer a reference for clinical practice, highlight key research priorities, and aim to improve patient outcomes on a global scale.
Author(s): Jeys LM, Morris GV, Kurisunkal VJ, Botello E, Boyle RA, Ebeid W, Houdek MT, Puri A, Ruggieri P, Brennan B, BOOM Consensus Meeting Participants, Laitinen MK
Publication type: Article
Publication status: Published
Journal: Bone & Joint Journal
Year: 2025
Volume: 107-B
Issue: 2
Pages: 246-252
Print publication date: 01/02/2025
Online publication date: 01/02/2025
Acceptance date: 02/04/2018
Date deposited: 24/02/2025
ISSN (print): 2049-4394
ISSN (electronic): 2049-4408
Publisher: British Editorial Society of Bone & Joint Surgery
URL: https://doi.org/10.1302/0301-620X.107B2.BJJ-2024-0643.R1
DOI: 10.1302/0301-620X.107B2.BJJ-2024-0643.R1
Data Access Statement: Data sharing for this study is available upon request from the corresponding author.
PubMed id: 39889743
Altmetrics provided by Altmetric
